Unos científicos han ideado un modo de usar aquafaba (el líquido resultante de cocer legumbres) y aceites vegetales para obtener grasas sólidas más saludables que la mantequilla, la margarina o la grasa de palma y capaces de reemplazar por completo a estas en productos de …
Uno de los mayores retos de la robótica social actual es conseguir que las máquinas interactúen con nosotros de forma natural y personalizada. Para lograrlo, una de las formas es que el robot sepa con quién está hablando. El grupo de robótica social …
Nuevo robot mascota que reconoce a las personas por su voz Read More »
The FDA cited problems with some of Zoll’s ventilators, automated external defibrillators and electrodes.
Zoll receives FDA warning letter over quality concerns Read More »
Employers are considering raising premiums and increasing other forms of cost sharing as they grapple with stubbornly rising health costs, according to a new survey from Mercer.
Employers plan to shift more health costs to employees Read More »
Joint Commission leaders break down the standards group’s new AI certification, explaining how it’s designed to work for everyone from major health systems to small rural clinics.
Can certification help solve healthcare’s AI governance gap? Read More »
UniQure’s planned third-quarter submission for its Huntington’s disease gene therapy may be a harbinger of a more flexible FDA under acting commissioner Kyle Diamantas—but how long will it last? And how can companies be sure these positive decisions won’t just be reversed?
At FDA, ‘caretaker mode’ is better than power trip mode Read More »
The international launch could benefit from Boston Scientific’s global footprint when the company closes its takeover of Penumbra.
Penumbra wins CE mark for Thunderbolt clot removal tech Read More »
The drug middlemen lobby has had a busy week. It’s the second major lawsuit the PCMA has filed against a state law reforming the PBM industry since Monday.
In this episode of Denatured, you’ll hear from Mark Lowdell, CSO & co-founder at INmuneBio Inc. and Vishwas Seshadri, CEO & director at Abeona Therapeutics. We explore how recessive dystrophic epidermolysis bullosa has become a defining case study for gene and cell therapy and what this ultra‑rare disease reveals about the future scalability of advanced
From fragile skin to living medicine: Lessons from RDEB Read More »
Durante décadas, colocar un implante dental dependió en gran medida de la pericia manual del cirujano y de su capacidad para interpretar radiografías en dos dimensiones. Hoy, ese mismo procedimiento empieza mucho antes de entrar en el quirófano: en una pantalla, …
